Back to Agenda
Drug Repurposing: Opportunities & Challenges
Session Chair(s)
Tamara Di Carlantonio, MA
Regulatory Policy Lead, Roche, Switzerland
Drug repurposing is regarded as a potential solution to treatment gaps and increasing healthcare costs, especially after COVID. However, this complex topic grants deeper discussion and a collaborative, multi-stakeholder approach.
Learning Objective : • Uncover the different aspects that come to play in drug repurposing: (including but not limited to) scientific, regulatory, patient access, healthcare systems, commercial • Articulate areas where repurposing presents opportunities • Describe current and potential challenges • Discuss how to tackle challenges in order to realize opportunities
Speaker(s)
Alberto Ganan Jimenez, PHD
Head of Committees and Quality Assurance, European Medicines Agency, Netherlands
EMA Repurposing Pilot
Donald Lo, PHD
Director of Medicines Development, EATRIS, Netherlands
Guillaume Canaud
Chief of the Overgrowth Syndromes and Vascular anomalies Unit, Neckar Enfants Malades Hospital, France
Targeted Therapy in PIK3CA-Related Overgrowth Syndrome
François Houyez
Treatment Information and Access Director, Health Policy Advisor, European Organisation for Rare Diseases (EURORDIS), France
Drug Repurposing: How to Proceed?
Solange Corriol-Rohou, DrMed, MD, PHD
, SCR Consulting, France
Panelist
Sini Eskola, MPHARM, MS, MSC
Head of International Regulatory Policy and Innovation, Takeda, Belgium
Panelist
Have an account?